Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation & Amortization (CF): 2016-2025

Historic Depreciation & Amortization (CF) for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to $100,000.

  • UroGen Pharma's Depreciation & Amortization (CF) changed negligibly% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $329,000, marking a year-over-year decrease of 35.87%. This contributed to the annual value of $329,000 for FY2024, which is 58.98% down from last year.
  • As of Q3 2025, UroGen Pharma's Depreciation & Amortization (CF) stood at $100,000, which was down 0.00% from $100,000 recorded in Q2 2025.
  • UroGen Pharma's 5-year Depreciation & Amortization (CF) high stood at $224,000 for Q4 2022, and its period low was $29,000 during Q4 2024.
  • For the 3-year period, UroGen Pharma's Depreciation & Amortization (CF) averaged around $132,636, with its median value being $100,000 (2025).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 143.90% in 2021, then slumped by 84.74% in 2024.
  • Over the past 5 years, UroGen Pharma's Depreciation & Amortization (CF) (Quarterly) stood at $213,000 in 2021, then climbed by 5.16% to $224,000 in 2022, then declined by 15.18% to $190,000 in 2023, then tumbled by 84.74% to $29,000 in 2024, then remained steady at $100,000 in 2025.
  • Its last three reported values are $100,000 in Q3 2025, $100,000 for Q2 2025, and $100,000 during Q1 2025.